Cinclus Pharma
20.5
SEK
+2.24 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+2.24%
+3.03%
-26.79%
-32.79%
-
-
-
-
-37.13%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
971.54M SEK
Turnover
1.47M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20/2
2025
Annual report '24
19/5
2025
Interim report Q1'25
22/5
2025
General meeting '24
ShowingAll content types
Linaprazan glurate receives marketing approval in China
Emission och återköp av C-aktier
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools